Protocol |
Title |
Status |
Contact |
103968 |
A Global Pivotal Study in Patients with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of Pembrolizumab and LY3537982 vs Pembrolizumab and Placebo in those with PD-L1 50% or Pembrolizumab, Pemetrexed, Platinum Chemotherapy and LY3537982 vs Pembrolizumab, Pemetrexed, Platinum Chemotherapy and Placebo regardless of PD-L1 Expression |
OPEN TO ACCRUAL |
|
103958 |
Phase 3 Study of Epcoritamab, Rituximab, and Lenalidomide for First-Line Treatment of Follicular Lymphoma |
OPEN TO ACCRUAL |
|
104069 |
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-North America) |
OPEN TO ACCRUAL |
|
103864 |
A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) |
OPEN TO ACCRUAL |
|
103981 |
A Phase 1 Study of NM32-2668 (Anti-ROR1/Anti-CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients with Selected Advanced Solid Tumors |
OPEN TO ACCRUAL |
|
103955 |
A Phase 1 Open Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications |
OPEN TO ACCRUAL |
|
104006 |
An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Dose-Expansion, Phase 1/2 Study of BBI-355 and BBI-355 in Combination with Select Targeted Therapies in Subjects with Locally Advanced or Metastatic Solid Tumors with Oncogene Amplifications |
OPEN TO ACCRUAL |
|
103713 |
A Phase II Study of Naxitamab Added to Induction Therapy for Subjects with Newly Diagnosed High-Risk Neuroblastoma |
OPEN TO ACCRUAL |
|
103989 |
A First-in-Human, Phase 1/2, Open-Label, Multi-Center, Dose Escalation, Dose-Optimization, and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of PARP1 Selective Inhibitor, IMP1734, in Patients with Advanced Solid Tumors |
OPEN TO ACCRUAL |
|
104031 |
Phase III Randomized Trial of Stereotactic ablative radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma |
OPEN TO ACCRUAL |
|
104013 |
A Phase 2 Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer |
OPEN TO ACCRUAL |
|
103834 |
Phase 1 Dose Escalation Study for a Trispecific Antibody (SAIL66), Targeting Solid Tumors Expressing CLDN-6 and CD3/CD137+ T-cells |
OPEN TO ACCRUAL |
|
103936 |
Phase 3 Study of Ficlatuzumab in Combination with Cetuximab in Subjects with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN) |
OPEN TO ACCRUAL |
|
103966 |
A Phase I/Randomized Phase II, Open-Label Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of mFOLFIRINOX With or Without BNT321 as Adjuvant Therapy Following Curative Resection in Patients with Pancreatic Adenocarcinoma |
OPEN TO ACCRUAL |
|
103905 |
A Phase II, Multicenter, Single-Arm Clinical Trial of Definitive Radiotherapy And CeMiPlimAb-Rwlc ImmunoTherapy for Locally Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: RAMPART |
OPEN TO ACCRUAL |
|
104067 |
A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable older adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study |
OPEN TO ACCRUAL |
|
103913 |
3068/217908 A Phase III Randomized Trial of Heated Intraperitoneal Chemotherapy (HIPEC) with Cisplatin versus no HIPEC at the Time of Optimal Interval Cytoreductive Surgery followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer |
OPEN TO ACCRUAL |
|
103868 |
A Randomized, Phase 2, Open-label Study of TransCon IL-2 B/y Monotherapy, TransCon IL-2 B/y in Combination with TransCon TLR7/8 Agonist, TransCon TLR7/8 Agonist in Combination with Pembrolizumab, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) |
OPEN TO ACCRUAL |
|
103517 |
Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer |
OPEN TO ACCRUAL |
|
103948 |
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants with Resected Stage II, IIIA, IIIB (N2) Non-Small Cell Lung Cancer |
OPEN TO ACCRUAL |
|